Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
1999 4
2000 7
2001 4
2002 5
2003 5
2004 6
2005 9
2006 5
2007 7
2008 4
2009 6
2010 10
2011 10
2012 22
2013 31
2014 39
2015 37
2016 36
2017 48
2018 49
2019 60
2020 75
2021 71
2022 70
2023 57
2024 61
2025 54
2026 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

757 results

Results by year

Filters applied: . Clear all
Page 1
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.
Garralda E, Schöffski P, Oberoi A, Schuler M, Richly H, Ascierto PA, Lin CC, Álvarez R, Patel SP, Xing Y, Subbiah V, Lewis N, Patel S, Wang-L-Akshman L, Lee JB, Hassounah NB, Lee LH, Roy M, Banerjee S, Reynolds A, Koyama T, Shimizu T. Garralda E, et al. Eur J Cancer. 2026 Jun 24;244:116899. doi: 10.1016/j.ejca.2026.116899. Online ahead of print. Eur J Cancer. 2026. PMID: 42407248
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.
Garbe C, Keim U, Amaral T, Ascierto PA, Bauer J, Dummer R, Eggermont AMM, Eigentler TK, Flatz L, Forchhammer S, Forschner A, Gandini S, Gershenwald JE, Hauschild A, Hoeller C, Kirkwood JM, Lebbe C, Long GV, Lorigan P, Luke JJ, Meier F, Metzler G, Nathan P, Postow MA, Robert C, Röcken M, Schadendorf D, Weide B, Whiteman D, Leiter U, Martus P. Garbe C, et al. Nat Commun. 2026 Jul 2;17(1):5790. doi: 10.1038/s41467-026-74443-9. Nat Commun. 2026. PMID: 42393046 Free PMC article.
Anti-PD-1 Combinations: Triplets and Beyond.
Trojaniello C, Marretta AL, Facchini BA, Ascierto PA. Trojaniello C, et al. Curr Oncol Rep. 2026 Jun 29;28(1):70. doi: 10.1007/s11912-026-01788-1. Curr Oncol Rep. 2026. PMID: 42366313 Free PMC article. Review.
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.
Naing A, Lin CC, Patel MR, Curigliano G, Burris HA, Thistlethwaite F, De Braud F, Minchom A, Ascierto PA, Wake M, Nguyen MA, Abbadessa G, Sainson RCA, Palu CC, Quaratino S, Deantonio C. Naing A, et al. J Immunother Cancer. 2026 Jun 8;14(6):e013540. doi: 10.1136/jitc-2025-013540. J Immunother Cancer. 2026. PMID: 42259602 Free PMC article. Clinical Trial.
Five-year survival with tebentafusp in metastatic uveal melanoma.
Piperno-Neumann S, Rutkowski P, Hassel JC, Butler MO, Schlaak M, Sullivan RJ, Dummer R, Kirkwood JM, Sacco JJ, Shoushtari AN, Piulats JM, Salama AKS, Orloff MM, Joshua AM, Ochsenreither S, Gastaud L, Curti BD, Demidov LV, Milhem MM, Chmielowski B, Kendra KL, Ascierto PA, Bernicker EH, Carvajal RD, Collins L, Lockwood S, Patel JM, Hamid OA, Baurain JF, Nathan PD. Piperno-Neumann S, et al. Among authors: ascierto pa. Ann Oncol. 2026 May 19:S0923-7534(26)00879-3. doi: 10.1016/j.annonc.2026.05.695. Online ahead of print. Ann Oncol. 2026. PMID: 42162665 Free article.
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.
Mandalà M, Chen MF, Sullivan RJ, Sergi MC, Postow M, Lawless AR, Effiom D, Peres T, Lorigan PC, Serra-Bellver P, Dummer R, Amaral T, Rasch ML, Giannarelli D, Vitale MG, Helgadottir H, Robert C, Ubaldi M, Johnson DB, Del Vecchio M, Indini A, Suijkerbuijk KPM, Nathan P, Carter T, Neyns B, Dirven I, Pires da Silva I, Menzies AM, Zimmer L, Livingstone E, Depenni R, Kähler K, Hauschild A, Spagnolo F, Di Giacomo AM, Arance A, Merelli B, Quaglino P, Rossi E, Tucci M, Guida M, Muñoz-Couselo E, Long GV, Larkin J, Ascierto PA. Mandalà M, et al. J Immunother Cancer. 2026 May 4;14(5):e015063. doi: 10.1136/jitc-2026-015063. J Immunother Cancer. 2026. PMID: 42082273 Free PMC article.
Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study.
Caraglia F, Argenziano G, Scala M, Sparano F, Del Giudice T, Sergi MC, Grimaldi AM, Forte M, Cozzolino S, Colloca A, Esposito A, Giugliano MC, Cioli E, Ottaviano M, Iavarone L, Franco R, Scharf C, Russo A, Cappabianca S, Ascierto PA, Nardone V, Formisano L, Napolitano S, Ciardiello D, Ciardiello F, Troiani T, De Falco V. Caraglia F, et al. Front Immunol. 2026 Apr 16;17:1738772. doi: 10.3389/fimmu.2026.1738772. eCollection 2026. Front Immunol. 2026. PMID: 42079618 Free PMC article.
757 results